211 related articles for article (PubMed ID: 19905999)
1. The role of serum PRL bioactivity evaluation in hyperprolactinaemic women with different menstrual disorders.
Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
Gynecol Endocrinol; 2009 Dec; 25(12):799-806. PubMed ID: 19905999
[TBL] [Abstract][Full Text] [Related]
2. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
[TBL] [Abstract][Full Text] [Related]
3. [Is the assessment of biological activity of prolactin essential in the diagnosis of hyperprolactinemia?].
Kostrzak A; Warenik-Szymankiewicz A; Meczekalski B
Pol Merkur Lekarski; 2010 May; 28(167):359-61. PubMed ID: 20568397
[TBL] [Abstract][Full Text] [Related]
4. Polycystic ovary syndrome or hyperprolactinaemia: a study of mild hyperprolactinaemia.
Su HW; Chen CM; Chou SY; Liang SJ; Hsu CS; Hsu MI
Gynecol Endocrinol; 2011 Jan; 27(1):55-62. PubMed ID: 20504100
[TBL] [Abstract][Full Text] [Related]
5. [Hyperprolactinemia and disorders of the menstrual cycle].
Topalski-Fistes N; Bujas M; Maticki-Sekulić M; Suvacarev S
Med Pregl; 1999; 52(3-5):156-61. PubMed ID: 10518402
[TBL] [Abstract][Full Text] [Related]
6. The importance of measuring macroprolactin in the differential diagnosis of hyperprolactinemic patients.
Lu CC; Hsieh CJ
Kaohsiung J Med Sci; 2012 Feb; 28(2):94-9. PubMed ID: 22313536
[TBL] [Abstract][Full Text] [Related]
7. The influence of latent hyperprolactinaemia on the levels of LH, FSH, E2 and T in the midfollicular phase of the cycle.
Kostál M; Tosner J
Arch Gynecol Obstet; 1997; 259(2):65-8. PubMed ID: 9059746
[TBL] [Abstract][Full Text] [Related]
8. Hyperprolactinaemia in polycystic ovary syndrome.
Lunde O
Ann Chir Gynaecol; 1981; 70(4):197-201. PubMed ID: 6797343
[TBL] [Abstract][Full Text] [Related]
9. The value of prolactin in predicting prolactinοma in hyperprolactinaemic polycystic ovarian syndrome.
Kyritsi EM; Dimitriadis GK; Angelousi A; Mehta H; Shad A; Mytilinaiou M; Kaltsas G; Randeva HS
Eur J Clin Invest; 2018 Jul; 48(7):e12961. PubMed ID: 29845629
[TBL] [Abstract][Full Text] [Related]
10. Serum retinol-binding protein 4 levels in nonobese women with polycystic ovary syndrome.
Chan TF; Tsai YC; Chiu PR; Chen YL; Lee CH; Tsai EM
Fertil Steril; 2010 Feb; 93(3):869-73. PubMed ID: 19028383
[TBL] [Abstract][Full Text] [Related]
11. Inappropriate gonadotropin secretion in polycystic ovary syndrome.
Hsu MI; Liou TH; Liang SJ; Su HW; Wu CH; Hsu CS
Fertil Steril; 2009 Apr; 91(4):1168-74. PubMed ID: 18325508
[TBL] [Abstract][Full Text] [Related]
12. Statistically significant changes of antimüllerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women.
Wunder DM; Bersinger NA; Yared M; Kretschmer R; Birkhäuser MH
Fertil Steril; 2008 Apr; 89(4):927-33. PubMed ID: 17603052
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
14. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
Song J; Shen H; Li J; Huang Z; Zhang Y
Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
[TBL] [Abstract][Full Text] [Related]
15. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
Baranowska B; Radzikowska M; Wasilewska-Dziubińska E; Kapliński A; Roguski K; Płonowski A
Gynecol Endocrinol; 1999 Oct; 13(5):344-51. PubMed ID: 10599552
[TBL] [Abstract][Full Text] [Related]
16. [Molecular heterogeneity of prolactin and gonadotropins in some forms of sterility].
Morán C; Fonseca ME; Ochoa R; Masón M; Gama R; Zárate A
Ginecol Obstet Mex; 1990; 58 Suppl 1():9-13. PubMed ID: 2125965
[TBL] [Abstract][Full Text] [Related]
17. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
18. Effect of metergoline on prolactin, follicle stimulating hormone, luteinizing hormone and thyroid stimulating hormone response to TRH and LHRH in normal men and women.
Sartani A; de Pasqua A; Cesati R; Farina L; Pontiroli AE
Horm Metab Res; 1984 Oct; 16(10):535-8. PubMed ID: 6437954
[TBL] [Abstract][Full Text] [Related]
19. Effect of Wujijing Oral Liquid on menstrual disturbance of women.
Geng SS; Li HZ; Wu XK; Dang JM; Tong H; Zhao CY; Liu Y; Cai YQ
J Ethnopharmacol; 2010 Apr; 128(3):649-53. PubMed ID: 20051257
[TBL] [Abstract][Full Text] [Related]
20. Serum resistin levels in women with polycystic ovary syndrome.
Panidis D; Koliakos G; Kourtis A; Farmakiotis D; Mouslech T; Rousso D
Fertil Steril; 2004 Feb; 81(2):361-6. PubMed ID: 14967374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
